Dispensing Evaluation of Investigational Contact Lenses

Not Applicable

Completed

• Conditions: Myopia; Astigmatism
• Interventions: Device: Prototype toric lens senofilcon A

• Registration Number: NCT02625220
• Lead Sponsor: Johnson & Johnson Vision Care, Inc.

Brief Summary

Non-randomized, single-masked, 2-visit, bilateral wear, single-arm dispensing study to evaluate the visual acuity, rotational performance, lens fit, stability and subjective characteristics of a senofilcon-based JJVCI investigational toric contact lens design.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-10
• Primary Completion: 2015-11
• Study Completion: 2015-11
• Study First Submitted: 2015-11-03
• Study First Submitted QC: 2015-12-04
• Study First Posted: 2015-12-09
• Results First Submitted: 2016-08-11
• Status Verified: 2017-05
• Results First Submitted QC: 2017-05-05
• Last Update Submitted: 2017-05-05
• Results First Posted: 2017-06-07
• Last Update Posted: 2017-06-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 177

Inclusion Criteria

• Healthy adult males or females that are ≥18 years of age and ≤39 years of age.
• The subject must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
• The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
• The subject must be a habitual toric contact lens wearer. Habitual wearer is defined as someone who wears toric lenses for at least 6 hours a day, 5 days a week for the past 30 days.
• Subject's vertex corrected spherical component of their distance refraction must be between -1.50 Diopters Sphere (DS) to -4.00 DS (inclusive) in each eye.
• Subject's vertex corrected refractive cylinder must be between -0.75 and -1.50 Diopters Cylinder (DC) (inclusive) in each eye.
• Subject's refractive cylinder axis must be within 180±15° and 90±15° in each eye.
• If needed, the subject must have a wearable pair of spectacles with 20/30 or better vision Ocular Uterque (OU). If spectacles are not needed, the subject must have 20/40 or better vision OU without correction.
• Subject's best corrected distance acuity must be 20/25-2 or better in each eye.

Exclusion Criteria

• Females who are currently pregnant or lactating.
• Any ocular or systemic allergies or diseases that may contraindicate contact lens wear.
• Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, and/or Stevens-Johnson syndromes, by self-report.
• Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV), by self-report.
• Habitual wearer of extended wear contact lenses.
• Any previous history of ocular and/or refractive surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.)
• History of seizures.
• Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by report.
• History of binocular vision abnormality or strabismus, by self-report.
• Habitual wearer of rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
• Employee and family members of employee of investigational clinic (e.g., Investigator, Coordinator, Technician).
• Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
• Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, and conjunctival injection) on the FDA classification scale.
• Any history of a contact lens-related corneal inflammatory event within the past year that may contraindicate contact lens wear.
• Any active ocular infection.
• Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
• Any fluctuations in vision due to clinically significant dry eye or other ocular conditions.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Prototype toric lens senofilcon A	Prototype toric lens senofilcon A	Subjects will wear the senofilcon A prototype toric contact lens bilaterally for 6-8 days as a daily disposable modality.

Primary Outcome Measures

Name	Time	Method
The Proportion of Eyes With Absolute Rotation Less Than or Equal to 10 Degrees	15 Minutes Post Insertion	Absolute rotation was measured using a slit lamp. Absolute rotation measured at 15-minute post insertion was categorized into a binary outcome as 'response=1' if the absolute rotation is less than or equal to 10 degrees or 'response=0' otherwise. The proportion of eyes with absolute rotation less than or equal to 10 degrees was reported.
Proportion of Eyes With Monocular Visual Acuity Better Than 20/40	7 day follow-up	Monocular visual acuity was assessed using distance Snellen visual acuity. Visual Acuity data was dichotomized such that 'response=1' if a subjects has 20/40 or better and 'response=0' if subject has worse than 20/40. The proportion of eyes with 20/40 or better was reported.
Proportion of Subjects Eyes With Lens Stability With Blink Within 5 Degrees	15 Minutes Post Insertion	Lens stability with blink was measured using a slit lamp. The rotational stability of the lens during a series of normal (unforced) blinks was measured for both eyes. The data was dichotomized as 'response=1' if the lens stability was less than or equal to 5 degrees or 'response=0' otherwise. The proportion of eyes with rotational stability of 5 degrees or lower was reported.
Proportion of Subject Eyes With Acceptable Lens Fit	15 Minute Post Insertion	Acceptability of contact lens fit was assessed via slit lamp and was reported as a binary response as Acceptable or Unacceptable. The proportion of eyes with acceptable fit was reported.

Trial Locations

Locations (12)

Edward S. Wygonik, OD; 🇺🇸 Jacksonville, Florida, United States

The Eye Center; 🇺🇸 Pembroke Pines, Florida, United States

Eye Associates of Winter Park; 🇺🇸 Winter Park, Florida, United States

Eyecare Associates; 🇺🇸 Bloomington, Illinois, United States

Indiana University College of Optometry; 🇺🇸 Bloomington, Indiana, United States

New Image Eye Center; 🇺🇸 Springfield, Ohio, United States

ABQ Eyecare; 🇺🇸 Albuquerque, New Mexico, United States

Sacco Eye Group; 🇺🇸 Vestal, New York, United States

Kannarr Eye Care; 🇺🇸 Pittsburg, Kansas, United States

Professional Vision Care; 🇺🇸 Westerville, Ohio, United States

Total Eye Care PA; 🇺🇸 Memphis, Tennessee, United States

West Bay Eye Associates; 🇺🇸 Warwick, Rhode Island, United States